-- KPI-012 is a novel secretome with a multifactorial mechanism of action for development in PCED and other orphan ocular surface diseases driven by impaired corneal healing ---- KPI-012 demonstrated ...
ARLINGTON, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative ...
ARLINGTON, Mass., Feb. 26, 2025 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results